array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(51) "Amgen to launch Eylea biosimilar after court ruling" ["snippet_en"]=> string(260) "Amgen will launch Pavblu, its biosimilar to Regeneron's Eylea, after a US Court of Appeals decision denied Regeneron's request to halt the launch. The ruling allows Amgen to expand access to its treatment despite Regeneron's ongoing patent infringement claims." ["url"]=> string(84) "https://www.aiche.org/news/industry/amgen-launch-eylea-biosimilar-after-court-ruling" ["image_url"]=> NULL ["source"]=> string(9) "aiche.org" ["publication_date"]=> string(10) "2024-11-04" ["categories"]=> array(5) { [0]=> string(10) "Litigation" [1]=> string(8) "Verdicts" [2]=> string(5) "Legal" [3]=> string(14) "Product Launch" [4]=> string(18) "Expansion & Growth" } } [1]=> array(7) { ["title_en"]=> string(131) "[Exclusive] Red flags for global launch of Samsung Bioepis’ ‘Eylea’… Following the US, the UK patent exhibition By The Guru" ["snippet_en"]=> string(368) "[The Guru = Reporter Han Ah-reum] A red flag has been raised regarding the global launch of Samsung Bioepis' macular degeneration treatment 'Eylea' (ingredient name: aflibercept). After losing a patent lawsuit against Regeneron, the original developer of Eylea, in the US in the first half of this year, the company was embroiled in a patent lawsuit in the UK as well." ["url"]=> string(63) "https://kr.investing.com/news/stock-market-news/article-1249121" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-10-31" ["categories"]=> array(4) { [0]=> string(5) "Fraud" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" [3]=> string(21) "Intellectual Property" } } [2]=> array(7) { ["title_en"]=> string(63) "Regeneron loses bid to block Amgen's launch of Eylea biosimilar" ["snippet_en"]=> string(205) "The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia, per a Reuters report." ["url"]=> string(82) "https://drugstorenews.com/regeneron-loses-bid-block-amgens-launch-eylea-biosimilar" ["image_url"]=> string(78) "https://images.businessradar.com/articles/030697ee-bdc1-46b8-b3fd-1ea66423331c" ["source"]=> string(17) "drugstorenews.com" ["publication_date"]=> string(10) "2024-10-30" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [3]=> array(7) { ["title_en"]=> string(78) "Regeneron loses Eylea biosimilar lawsuit... Continuation of the appeal process" ["snippet_en"]=> string(341) "[The Bio Reporter Seong Jae-jun] Regeneron, an American biotechnology company, lost a lawsuit filed to block the launch of a biosimilar of the blockbuster eye treatment Elyea (ingredient aflibercept). Recently, the U.S. Federal Circuit Court Last month, a West Virginia federal court granted Regeneron's request for a preliminary injunction." ["url"]=> string(59) "https://www.thebionews.net/news/articleView.html?idxno=9800" ["image_url"]=> NULL ["source"]=> string(14) "thebionews.net" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [4]=> array(7) { ["title_en"]=> string(63) "Regeneron Fails to Block Amgen's Eylea Biosimilar During Appeal" ["snippet_en"]=> string(257) "Regeneron Pharmaceuticals Inc. failed to block Amgen Inc.'s biosimilar of Eylea while it appeals a West Virginia federal judge’s denial of Regeneron’s request for a preliminary injunction, though the Federal Circuit said it will expedite the proceeding." ["url"]=> string(99) "https://news.bloomberglaw.com/ip-law/regeneron-fails-to-block-amgens-eylea-biosimilar-during-appeal" ["image_url"]=> NULL ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [5]=> array(7) { ["title_en"]=> string(105) "District Court Denies Regeneron’s Motion For Preliminary Injunction To Block Amgen’s Eylea Biosimilar" ["snippet_en"]=> string(153) "On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) motion for a..." ["url"]=> string(76) "https://www.jdsupra.com/legalnews/district-court-denies-regeneron-s-6578645/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b1642acf-eca9-4bf6-88d8-5984966fce1a" ["source"]=> string(11) "jdsupra.com" ["publication_date"]=> string(10) "2024-10-22" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [6]=> array(7) { ["title_en"]=> string(64) "Regeneron 'Safe Harbor' Argument Rejected in Covid Cocktail Suit" ["snippet_en"]=> string(253) "Regeneron Pharmaceuticals Inc.’s infringement of a California biotechnology company’s patent for technology used to develop its Covid-19 “antibody cocktail” isn’t immunized by the US Patent Act’s safe harbor provision, a federal judge ruled." ["url"]=> string(99) "https://news.bloomberglaw.com/ip-law/regeneron-safe-harbor-argument-rejected-in-covid-cocktail-suit" ["image_url"]=> NULL ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2024-10-05" ["categories"]=> array(4) { [0]=> string(8) "Epidemic" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" [3]=> string(21) "Intellectual Property" } } [7]=> array(7) { ["title_en"]=> string(63) "Biocon Pushes to Unseal Amgen Eylea Court Filings Before Appeal" ["snippet_en"]=> string(293) "Amgen Inc. is “stonewalling” public access to information about its successful avoidance of Regeneron Pharmaceuticals Inc.’s bid to block its biosimilar of the blockbuster eye drug Eylea, two competitors said in a filing urging a judge to release a trove of sealed documents in the case." ["url"]=> string(100) "https://news.bloomberglaw.com/ip-law/biocon-pushes-to-unseal-amgen-eylea-court-filings-before-appeal" ["image_url"]=> NULL ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2024-10-01" ["categories"]=> array(4) { [0]=> string(14) "Product Launch" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" [3]=> string(8) "Verdicts" } } [8]=> array(7) { ["title_en"]=> string(111) "Fed­er­al judge rules against Re­gen­eron's at­tempt to halt Am­gen from launch­ing Eylea biosim­i­lar" ["snippet_en"]=> string(301) "Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its blockbuster eye treatment Eylea. While Regeneron previously defended itself in court from imminent competition, the US District Court for the Northern District of West Virginia" ["url"]=> string(76) "https://endpts.com/regeneron-hits-setback-in-eylea-patent-battle-with-amgen/" ["image_url"]=> NULL ["source"]=> string(10) "endpts.com" ["publication_date"]=> string(10) "2024-09-25" ["categories"]=> array(5) { [0]=> string(12) "Stock Market" [1]=> string(10) "Litigation" [2]=> string(21) "Competitive Behaviour" [3]=> string(5) "Legal" [4]=> string(8) "Verdicts" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc